Taken together, these findings suggest that METTL3‐mediated SREBP1c upregulation contributes to AKI and its progression to CKD through disrupting mitochondrial energy metabolism via transcriptionally suppressing YME1L1. This evidence concerns the gene METTL3 and chronic kidney disease.